Immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: The critical role of subgroup analyses

iLiver · Published 2025-11-14 · DOI 10.1016/j.iliver.2025.100208

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.iliver.2025.100208

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Medical imaging-derived artificial intelligence for prognostic stratification and treatment response prediction in interventional therapy of hepatocellular carcinoma · iLiver · 2026 · Same journal
• Advances in magnetic resonance imaging for the evaluation of colorectal liver metastases in context of individualized precision medicine · iLiver · 2025 · Same journal
• Application of the Laennec approach in laparoscopic repeat liver resection · iLiver · 2026 · Same journal
• Surgical treatment of refractory groove pancreatitis · iLiver · 2026 · Same journal
• MAGI2-AS3/miR-450b-5p/COLEC10 interaction network: A potential therapeutic and prognostic marker in hepatocellular carcinoma · iLiver · 2025 · Same journal
• New approaches to the treatment of metabolic dysfunction-associated steatotic liver with natural products · iLiver · 2024 · Same journal
• Itaconate facilitates methane-induced Nrf2 pathway activation for mitigating liver ischemia and reperfusion injury · iLiver · 2025 · Same journal
• Progress on Laennec's capsule guidance for hepatobiliary surgery · iLiver · 2025 · Same journal
• Artificial intelligence in hepatology: A comprehensive scoping review of clinical applications, challenges, and future directions · iLiver · 2025 · Same journal
• Danning tablets for the treatment of multiple gallbladder polyps: Study protocol of multicentre, randomised, open-labelled, controlled trial · iLiver · 2024 · Same journal